Skip to main content
Clinical Trials/ITMCTR2100004996
ITMCTR2100004996
Not yet recruiting
Phase 4

A randomized, controlled, multicentre clinical study of Shengu Capsule in the treatment of postmenopausal osteoporosis (deficiency syndrome of liver and kidney)

Fujian Academy of Chinese Medical Sciences0 sitesTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Fujian Academy of Chinese Medical Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
Female

Investigators

Sponsor
Fujian Academy of Chinese Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • 1\.Meet the diagnostic criteria for postmenopausal osteoporosis;
  • 2\.Meet the TCM syndrome differentiation standard of liver and kidney deficiency;
  • 3\.Voluntarily signed informed consent;
  • 4\.Age between 45 and 70 years old;
  • 5\.Female have been naturally menopausal for more than 1 yearr.

Exclusion Criteria

  • 1\.Those with secondary osteoporosis such as hyperparathyroidism, rheumatoid arthritis, multiple myeloma, type I diabetes, etc;
  • 2\.People with mental illness or Alzheimer's;
  • 3\.People with allergies or those who are known to be allergic to the ingredients in this medicine;
  • 4\.Those who are in a critical condition and are difficult to make an accurate assessment of the effectiveness and safety of the drug;
  • 5\.Patients with hypercalcemia and hypercalciuria.

Outcomes

Primary Outcomes

Not specified

Similar Trials